Research Topics
| V BitonSummaryAffiliation: University of Kentucky Country: USA Publications
|
Detail Information
Publications
Clinical pharmacology and mechanism of action of zonisamideVictor Biton
Arkansas Epilepsy Program, Little Rock, AR, USA
Clin Neuropharmacol 30:230-40. 2007....- Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsyVictor Biton
Arkansas Epilepsy Program, 2 Lile Court, Suite 100, Little Rock, AR 72205, USA
CNS Drugs 17:781-91. 2003..The most appropriate therapeutic choice is a weight-neutral medication unless circumstances dictate otherwise... - Pharmacokinetics, toxicology and safety of lamotrigine in epilepsyVictor Biton
Arkansas Epilepsy Program, Little Rock, AR, USA
Expert Opin Drug Metab Toxicol 2:1009-18. 2006..The pharmacokinetic, toxicology and safety profiles of lamotrigine make the drug suitable for use across a spectrum of patients with epilepsy... - Weight change and antiepileptic drugs: health issues and criteria for appropriate selection of an antiepileptic agentVictor Biton
Arkansas Epilepsy Program, Little Rock, Arkansas 72205, USA
Neurologist 12:163-7. 2006..Weight change, either gain or loss, is a common AED side effect, conferring multiple risks of additional morbidity... - Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizuresV Biton
Arkansas Epilepsy Program, Little Rock, AR 72205, USA
Neurology 65:1737-43. 2005..To evaluate the efficacy and tolerability of adjunctive lamotrigine in primary generalized tonic-clonic (PGTC) seizures in a randomized, double-blind, placebo-controlled trial... - Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsyV Biton
Arkansas Epilepsy Program, Little Rock 72205, USA
Neurology 56:172-7. 2001..Weight gain associated with valproate was significant within 10 weeks after initiating therapy and continued throughout the study. Efficacy of lamotrigine was comparable with that of valproate; lamotrigine tended to be better tolerated... - A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study GroupV Biton
Arkansas Epilepsy Program, Little Rock 72205, USA
Neurology 52:1330-7. 1999..The efficacy and safety of topiramate as adjunctive therapy for the treatment of primary generalized tonic-clonic (PGTC) seizures were investigated in a randomized, double-blind, placebo-controlled study... - Topiramate titration and tolerabilityV Biton
Arkansas Epilepsy Program, Little Rock 72205, USA
Ann Pharmacother 35:173-9. 2001..To evaluate the tolerability and efficacy of two titration rates for topiramate initiated as adjunctive therapy in adults with partial-onset seizures, with or without secondary generalization, in a multicenter, double-blindtrial... - Zonisamide: newer antiepileptic agent with multiple mechanisms of actionVictor Biton
Two Lile Court, Suite 100, Little Rock, AR 72205, USA
Expert Rev Neurother 4:935-43. 2004..A review of the chemical properties, pharmacokinetics, metabolism, potential mechanisms of action, efficacy in seizure and nonseizure disorders, and tolerability was therefore thought to be timely... - Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trialVictor Biton
Arkansas Epilepsy Program, Little Rock 72205, USA
J Child Neurol 18:133-9. 2003..quot; Whereas weight remained stable in adolescents treated with lamotrigine, weight increased in those treated with valproate by week 10 of this study and continued to increase at the end of the study... - Topiramate in patients with juvenile myoclonic epilepsyVictor Biton
Arkansas Epilepsy Program, Little Rock 72205, USA
Arch Neurol 62:1705-8. 2005..Juvenile myoclonic epilepsy is one of the most common idiopathic generalized epilepsies, with most patients experiencing PGTCS... - Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizuresVictor Biton
Arkansas Epilepsy Program, Little Rock, Arkansas 77025, USA
Epilepsia 49:418-24. 2008..This multicenter, double-blind, double-dummy, randomized, inpatient trial evaluated the safety, tolerability, and pharmacokinetics of intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures... - A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsyMark E Sale
Pharmacokinetic Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, NC, USA
Epilepsy Behav 6:63-70. 2005.... - Levetiracetam and partial seizure subtypes: pooled data from three randomized, placebo-controlled trialsIlo E Leppik
MINCEP Epilepsy Care and University of Minnesota, 5775 Wayzata Boulevard, Suite 255, Minneapolis, MN 55416, USA
Epilepsia 44:1585-7. 2003..To determine the effect of levetiracetam (LEV) on partial seizure subtypes (simple partial, complex partial, and secondarily generalized seizures) in patients with refractory epilepsy... - Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizuresElinor Ben-Menachem
Sahlgrenska Academy at Goteborg University, Goteborg, Sweden
Epilepsia 48:1308-17. 2007.... - Divalproex-ER pharmacokinetics in older children and adolescentsSandeep Dutta
Abbott Laboratories, Abbott Park, Illinois, USA
Pediatr Neurol 30:330-7. 2004.... - Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled studyRichard L Rauck
The Center for Clinical Research, Winston Salem, NC, USA
Clin J Pain 23:150-8. 2007..Peripheral diabetic neuropathy affects between 20% and 45% of patients with diabetes...